What Is Tesamorelin? GHRH Peptide for Visceral Fat Research

What Is Tesamorelin?

Tesamorelin (CAS 218949-48-9, approximate MW 5135 Da) is a synthetic analogue of GHRH — growth hormone-releasing hormone. It is the full 44-amino acid sequence of endogenous human GHRH with a single key modification: a trans-3-hexenoic acid group conjugated to the N-terminal tyrosine residue.

This modification improves resistance to DPP-IV (dipeptidyl peptidase IV), the enzyme that degrades GHRH in plasma. The result is a compound that retains the full receptor binding affinity of endogenous GHRH while lasting longer in physiological conditions — making it a more practical research tool than native GHRH, which degrades too rapidly for many in-vivo protocols.

Tesamorelin is notable in the research peptide landscape for having a completed clinical development pathway. Under the brand name Egrifta, it received FDA approval in 2010 for reducing excess visceral fat in HIV-infected patients with lipodystrophy — providing an unusually strong evidence base compared to research compounds that exist solely in preclinical data.

The Mechanism: Pituitary GH Stimulation → Lipolysis

Unlike GLP-1 agonists (Retatrutide, Semaglutide, Tirzepatide) that suppress appetite to reduce body weight, Tesamorelin works through an entirely different pathway:

1. Tesamorelin binds GHRH receptors on pituitary somatotroph cells
2. Pituitary releases GH in pulsatile bursts — mimicking the body's natural overnight GH surge
3. GH stimulates IGF-1 production in the liver
4. GH directly activates hormone-sensitive lipase in adipose tissue → lipolysis (fat breakdown)
5. Visceral adipose tissue is particularly sensitive to GH-driven lipolysis — more so than subcutaneous fat

This pathway produces fat reduction without appetite suppression — making it a valuable tool for dissecting GH-mediated fat metabolism from caloric intake effects in research models.

Key Research Areas

Visceral Fat Reduction

The most extensively studied application for Tesamorelin is visceral fat reduction. In the HIV lipodystrophy trials that led to FDA approval, Tesamorelin consistently reduced visceral adipose tissue as measured by CT scan, with statistically significant reductions at 26 weeks maintained at 52 weeks. Visceral fat (the deep abdominal fat surrounding internal organs) is particularly associated with metabolic disease and is driven partly by GH deficiency.

Growth Hormone Axis Research

Tesamorelin is the preferred tool when researchers need to study the GHRH → GH → IGF-1 axis with the closest available match to endogenous GHRH signalling. Its full 44-residue sequence preserves all the contact points between GHRH and its receptor that shorter analogues may miss.

Body Recomposition

GH stimulation by Tesamorelin produces downstream IGF-1 elevation, which in animal and human research has been associated with shifts in lean muscle and fat distribution — providing a research tool for studying body recomposition independently of caloric intake changes.

Cognitive Function — Emerging Research

A growing area of interest involves the role of GH and IGF-1 in brain function. IGF-1 receptors are expressed in brain regions associated with memory and learning (hippocampus, frontal cortex). Tesamorelin has been studied in early-stage research for potential effects on memory and cognitive health in ageing models, where GH/IGF-1 axis activity naturally declines.

Tesamorelin vs Other GHRH Analogues

Reconstitution and Storage

Add 1–2mL of bacteriostatic water to the lyophilised vial. Inject slowly along the inside wall of the vial — do not shake or vortex. Gently swirl until dissolved. The solution should be clear and colourless. Store lyophilised at −20°C for up to 24 months. Store reconstituted solution at 2–8°C for up to 4 weeks, protected from light.

Disclaimer: Tesamorelin is a research compound for in-vitro laboratory use only. It is not approved for human consumption outside of its specific medical indication (Egrifta — prescription only). All information here relates to research applications. Not for unsupervised human use.